## Bold Move to Focus on Pharma Solutions
Specialty packaging manufacturer Gerresheimer surprised investors with a radical strategic decision, announcing the divestment of its entire moulded glass business. The move, revealed late Tuesday, sent shares soaring 6% in after-hours trading. The division, which generated €735 million in revenue in 2024 with a robust 20% adjusted EBITDA margin, includes eight production sites across Germany, Belgium, Italy, the U.S., and India, employing 3,700 workers. Despite its profitability, management believes the unit’s growth potential lies outside the group, opting instead to pivot exclusively toward high-margin pharmaceutical and biotech solutions, including primary packaging and drug delivery systems.
Should investors sell immediately? Or is it worth buying Gerresheimer?
## Investor Optimism Ahead of Key Update
The market welcomed the news as a sign of sharper focus, with shares climbing further on Tradegate. The recent acquisition of Bormioli Pharma’s glass business had already positioned Gerresheimer as a leader in integrated systems, and this divestment accelerates its transformation. Details on the sale process and broader strategy will be unveiled at the Capital Market Day on October 15, 2025, keeping speculative interest alive. Analysts suggest the shift aligns with higher-growth segments, though execution risks remain.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from February 7 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Gerresheimer: Buy or sell? Read more here...
